Markets:

Overview

News

Currencies

International

Treasuries

Hikma Pharms Plc ADR (OP:HKMPY)

34.64 +1.21 (+3.62%)

Streaming Delayed Price Updated: 2:27 PM EDT, Mar 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Hikma Pharms Plc ADR

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

March 20, 2025

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada

From Emergent BioSolutions

Via GlobeNewswire

Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production ↗

September 06, 2024

Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.

Via Benzinga

Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices ↗

August 28, 2024

Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and...

Via Benzinga

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

January 08, 2024

From Guardant Health, Inc.

Via Business Wire

Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape ↗

June 12, 2023

The FDA is actively seeking new suppliers to address the shortages of methotrexate, a widely used cancer drug in short supply since March. Methotrexate is an injected medication utilized to treat...

Via Benzinga

Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

December 26, 2022

From Junshi Biosciences

Via GlobeNewswire

Friday Markets News ↗

March 25, 2022

Methane leaks in the Permian Basin are 6 times higher than estimates.

Via Talk Markets

Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)

August 27, 2021

From Bio-Thera Solutions, Ltd.

Via Business Wire

Summer Friday ↗

June 25, 2021

The stock market tried for another record after yesterday's late blowout over the infrastructure deal.

Via Talk Markets

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.